EXACT Therapeutics’ Promising Pancreatic Cancer Study: A Closer Look

EXACT Therapeutics AS ((DE:56F)) announced an update on their ongoing clinical study.

EXACT Therapeutics AS is conducting a Phase 2 clinical study titled ‘A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer.’ The study aims to evaluate the effectiveness and safety of combining Acoustic Cluster Therapy (ACT) with chemotherapy for treating locally advanced pancreatic cancer, a condition with limited treatment options.

The intervention being tested is a combination of Acoustic Cluster Therapy, which involves a drug (PS101) and an ultrasound device, alongside Modified FOLFIRINOX, a chemotherapy regimen. This combination is intended to enhance the treatment’s efficacy against pancreatic cancer.

The study follows an interventional design with a single-group model and no masking, focusing on treatment as its primary purpose. This straightforward design allows for direct observation of the treatment’s effects on participants.

The study began on January 15, 2025, with primary completion expected soon. The latest update was submitted on August 29, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

This clinical update could influence EXACT Therapeutics’ stock performance positively, as successful results may enhance their market position in cancer treatment. Investors should watch for developments, considering the competitive landscape in oncology therapeutics.

The study is ongoing, and further details are available on the ClinicalTrials portal.